1. Home
  2. PMM vs SGHT Comparison

PMM vs SGHT Comparison

Compare PMM & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Putnam Managed Municipal Income Trust

PMM

Putnam Managed Municipal Income Trust

HOLD

Current Price

$6.23

Market Cap

258.7M

Sector

Finance

ML Signal

HOLD

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$3.81

Market Cap

187.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMM
SGHT
Founded
1989
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
258.7M
187.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PMM
SGHT
Price
$6.23
$3.81
Analyst Decision
Buy
Analyst Count
0
7
Target Price
N/A
$9.08
AVG Volume (30 Days)
113.0K
243.4K
Earning Date
01-01-0001
05-07-2026
Dividend Yield
4.68%
N/A
EPS Growth
N/A
28.16
EPS
0.23
N/A
Revenue
N/A
$77,363,000.00
Revenue This Year
N/A
$11.67
Revenue Next Year
N/A
$10.39
P/E Ratio
$26.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.70
$2.40
52 Week High
$6.52
$9.24

Technical Indicators

Market Signals
Indicator
PMM
SGHT
Relative Strength Index (RSI) 54.78 46.50
Support Level $6.07 $3.29
Resistance Level $6.36 $4.29
Average True Range (ATR) 0.09 0.20
MACD 0.03 0.08
Stochastic Oscillator 87.18 58.33

Price Performance

Historical Comparison
PMM
SGHT

About PMM Putnam Managed Municipal Income Trust

Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

Share on Social Networks: